037 Open-Label Pilot, Prospective Vulvoscopic Study of Daily Administration of Prasterone Vaginal Inserts in Women with Moderate to Severe Dyspareunia

Abstract

Prasterone (DHEA), a daily 6.5 mg vaginal insert, is FDA approved for moderate to severe dyspareunia, a symptom of vulvovaginal atrophy from menopause. Prasterone is converted intracellularly in vaginal wall layers into active androgens and estrogens with blood values maintained within normal post-menopausal range. Although prasterone is a vaginal insert, the significant reduction of pain in the phase 3 trials suggests improvement of the vestibular, endodermal genital tissue associated with dyspareunia in androgen and estrogen deficient states like menopause.